explore -WSS

explore

author：knowledge 2025-10-01 18:34:58 - browse：1

insulin biosimilar — Last week, the FDA released a trio of guidelines clarifying the way they plan to evaluate devices that go through the 510(k) pathway. Jacquelyn Martin/AP

Five years after promising to fix a flawed regulatory pathway widely used by medical device manufacturers, the Food and Drug Administration has issued new guidelines to improve its so-called 510(k) program that has long been lambasted for letting risky devices fall through the cracks.

Most medical device companies do not have to test their products on people in order to secure clearance from the FDA — they simply have to show they’re “substantially equivalent” to devices already on the market, called “predicates.” This process is the 510(k) pathway, and accounts for the vast majority of new medical devices launched on the market each year. Devices cleared through this pathway include X-ray machines, muscle stimulators, and wheelchairs.

Last week, the FDA released a trio of guidelines clarifying the way it plans to evaluate devices that go through the 510(k) pathway. The agency is asking manufacturers to avoid predicate devices that were recalled due to a “design-related” issue or have “unmitigated” safety concerns. Manufacturers should submit flow charts explaining why they chose their predicate device. If they have to choose one with a recall history or safety issues, they should explain how the new device addresses those problems. The FDA may also ask the manufacturer for clinical data in this case.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Digital health: a case of mistaken identity

hotspot

WSS

Why CTE doesn’t keep Americans from enjoying the Super Bowl

Global cancer cases to surge 77% by 2050, WHO report says

Updated Covid vaccine has 54% effectiveness, new study suggests

Texas Medical Board asked to define abortion emergency exception

AI gets buy

Adopting new red light myopia treatments may be short

hotspot

explore

knowledge

Medicare details structure of new drug price negotiation program

What’s missing from the debate over nursing home staff minimums

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Unique patient identifier: Experts argue the benefits, pitfalls

BioMarin wins approval for gene therapy to treat hemophilia A

The CDC's new social media misinformation war

Dobbs anniversary: the lost opportunity of abortion as health care

As a primary care physician, here's how I hope to partner with AI

Tori Bowie and the unacceptable rates of Black maternal death

AI gets buy

knowledge

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

Investigation reveals sickle cell patients pressured into sterilizations

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

H5N1 virus can be tracked in retail milk, scientists say

Readout Newsletter: Amgen, Regeneron, BGI Group and more

Gene therapy for Afghan refugees’ infant will be fully covered

hotspot

focus

hotspot

entertainment